[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stable-angina-pectoris\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stable-angina-pectoris":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,80,111,138,164,197,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100638846","effect-of-periodontal-therapy-on-asprosin-in-stable-angina-100638846",false,"NCT07591844","Effect of Periodontal Therapy on Asprosin in Stable Angina","Effect of Non-Surgical Periodontal Therapy on Serum Asprosin in Patients With Stable Angina","Inclusion Criteria:\n\n* Willingness to participate in the study and provide written informed consent\n* Age 18 years or older\n* No periodontal treatment within the past 6 months\n* No use of local or systemic antibiotics within the past 3 months\n\nExclusion Criteria:\n\n* Unwillingness to participate in the study or to provide informed consent\n* Age under 18 years\n* Use of local or systemic antibiotics for the treatment of widespread infection within the past 3 months\n* Receipt of periodontal treatment within the past 6 months\n* Pregnancy or lactation (for female participants)\n* History of acute myocardial infarction within the past 6 months",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effect of non-surgical periodontal therapy on serum asprosin levels in patients with stable angina and periodontitis. Asprosin is a novel metabolic biomarker reported to have potential protective roles in cardiovascular diseases and inflammatory processes. The study also investigates the relationship between periodontal parameters and serum asprosin levels before and after periodontal therapy.",[28,29],"Stable Angina Pectoris","Periodontitis",[31,32,33,34,35],"Non-surgical periodontal treatment","cardiovascular disease","stable angina","asprosin","periodontitis","NOT_YET_RECRUITING","2026-05-11",{"date":39,"type":40},"2026-05-18","ACTUAL",{"date":42,"type":22},"2026-05-20",{"date":44,"type":22},"2026-10-20",{"name":46,"class":47},"Ondokuz Mayıs University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100637356","phase-4-1-or-6-months-of-dual-antiplatelet-therapy-after-drug-coated-balloon-angioplasty-for-de-novo-small-coronary-artery-disease-100637356","NCT07592507","1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease","1 or 6 Months of Dual Antiplatelet Therapy After Drug-Coated Balloon Angioplasty for De Novo Small Coronary Artery Disease: An Open-label, Randomized, Non-inferiority Trial","D-ONE","Inclusion Criteria:\n\n* 1)Adults aged 19 years or older 2)Subjects who have undergone drug-coated balloon (DCB) angioplasty 3) Subjects with stable angina, asymptomatic ischemia, and angiographically confirmed coronary lesions 4)Patients who have not undergone coronary intervention and whose coronary angiography demonstrates a reference vessel diameter between 2.0 mm and 3.0 mm, meeting all of the following conditions: No severe dissection corresponding to National Heart, Lung, and Blood Institute (NHLBI) grade C to F No reduction in coronary blood flow defined as TIMI flow grade \\\u003C 2 No residual stenosis ≥ 30% 5)Patients newly diagnosed with small-vessel coronary artery disease among those maintained on single antiplatelet therapy (SAPT) for at least 6 months after undergoing: de novo percutaneous coronary intervention (de novo PCI),in-stent restenosis PCI (ISR PCI), or percutaneous transluminal coronary angioplasty (PTCA) 6)Subjects who voluntarily agree to participate in this clinical study and provide written informed consent\n\nExclusion Criteria:\n\n* 1\\) Patients diagnosed with Acute Coronary Syndrome (ACS), including STEMI, NSTEMI, or Unstable Angina.\n\n  2\\) Patients undergoing concomitant Percutaneous Coronary Intervention (PCI) during the Drug-Coated Balloon (DCB) procedure.\n\n  3\\) Patients undergoing PCI for In-Stent Restenosis (ISR). 4) Patients with a diagnosis of active bleeding or coagulation disorder within 2 months prior to obtaining informed consent.\n\n  5\\) Patients who underwent surgery with moderate-to-high risk within 6 weeks prior to obtaining informed consent.\n\n  6\\) Patients with a history of intracerebral hemorrhage (ICH). 7) Patients with Hemoglobin \\\u003C 10 g\u002FdL or Platelet count \\\u003C 100 x 10³\u002Fmm³. 8) Patients unable to discontinue oral anticoagulation therapy (OAC). 9) Patients on long-term treatment with NSAIDs or COX-2 inhibitors (excluding aspirin).\n\n  10\\) Patients with a life expectancy of less than 1 year due to malignancy or other comorbidities.\n\n  11\\) Patients with moderate-to-severe hepatic impairment. 12) Patients at risk of symptomatic bradycardia (e.g., 2nd-degree Mobitz Type II block or 3rd-degree AV block).\n\n  13\\) Patients with dyspnea, such as those with Chronic Obstructive Pulmonary Disease (COPD).\n\n  14\\) Patients with intolerance or hypersensitivity to the investigational medicinal products.\n\n  15\\) Patients who participated in other clinical trials within 3 months prior to informed consent (excluding non-interventional observational studies).\n\n  16\\) Women who are pregnant or breastfeeding. 17) Patients with End-Stage Renal Disease (ESRD) on hemodialysis or peritoneal dialysis, or those who have undergone a kidney transplant.\n\n  18\\) Patients with rare hereditary metabolic disorders, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n\n  19\\) Any patient deemed unsuitable for participation in the clinical trial at the investigator's discretion.","19 Years",{"count":59,"type":22},1484,[61],"PHASE4","1. Objective Objective: \\> The purpose of this study is to evaluate whether a short-term (1-month) dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) is non-inferior to the standard 6-month DAPT in patients undergoing Drug-Coated Balloon (DCB) angioplasty for de novo small coronary artery disease.\n\n   Methods: \\> This is an open-label, randomized, non-inferiority trial. Patients will be assigned to either 1 month or 6 months of DAPT after successful DCB treatment. The study will compare the incidence of Net Adverse Clinical Events (NACE)-a composite of cardiovascular death, myocardial infarction, target vessel revascularization, and major bleeding-between the two groups from 1 to 12 months post-procedure.\n2. Background Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is essential to prevent stent thrombosis and ischemic events. While short-duration DAPT (e.g., 4 weeks) has shown benefits in patients at high bleeding risk, evidence regarding the optimal DAPT duration specifically after Drug-Coated Balloon (DCB) angioplasty for small vessel disease remains insufficient. This study aims to fill this clinical gap by comparing 1-month versus 6-month DAPT strategies.\n\nPrimary Objective To demonstrate the non-inferiority of 1-month DAPT (followed by SAPT up to 12 months) compared to 6-month DAPT in terms of Net Adverse Clinical Events (NACE) occurring between 1 and 12 months post-randomization.\n\nSecondary Objectives To evaluate ischemic safety (CV death, MI, TLR). To assess bleeding safety (BARC type 2, 3, or 5). To analyze individual components of the primary composite endpoint, including all-cause death and stent thrombosis.",[28,64],"Coronary Artery Disease",[66,67,68,69,70,71,72],"DAPT","aspirin","clopidogrel","drug coated balloon","DCB","dual antiplatelet therapy","small vessel disease",{"date":39,"type":40},{"date":75,"type":22},"2026-05",{"date":77,"type":22},"2032-02",{"name":79,"class":47},"Daejeon St. Mary's hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100638027","ai-enhanced-single-lead-ecg-screening-for-coronary-stenosis-100638027","NCT07579624","AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis","Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements","Inclusion Criteria:\n\n* Presence of written informed consent from the patient to participate in the study.\n* Age 18 years and older.\n* Outpatient visit and\u002For hospitalization at the research center with coronary visualization performed.\n\nNon-inclusion criteria:\n\n* Absence of sufficient data on coronary anatomy and stenosis significance.\n* Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).\n* Absence of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n* Patient's unwillingness to continue participation in the study.\n* Inability to perform full analysis of single-channel ECG digital characteristics.\n* Refusal of coronary visualization methods for any reason.",{"count":88,"type":22},400,"OBSERVATIONAL","It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.\n\nAll study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.\n\nStress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.\n\nAll patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.",[92,93,28,94],"Ischemic Heart Disease","Coronary Artery Stenosis","Acute Coronary Syndromes",[96,92,97,98,99,100,101],"coronary","Single-Channel ECG","Artificial Intelligence","AI-Enhanced Screening","Non-Invasive Diagnostics","Angina","2026-05-06",{"date":104,"type":40},"2026-05-12",{"date":106,"type":22},"2026-05-01",{"date":108,"type":22},"2027-12-01",{"name":110,"class":47},"I.M. Sechenov First Moscow State Medical University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100627470","comprehensive-invasive-physiological-evaluation-of-obstructive-coronary-artery-disease-100627470","NCT07449052","Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease","Inclusive Invasive Physiological Assessment in Angina Syndromes - Obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.\n\nExclusion Criteria:\n\n* Prior coronary artery bypass graft surgery.\n* Stenosis \\>90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation\n* Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)\n* Severe valvular disease\n* Renal impairment (estimated glomerular filtration rate \\\u003C30mL\u002Fmin)\n* Contra-indications for the use of adenosine or acetylcholine\n* Expected inability to conform to the clinical follow-up\n* Unable or unwilling to use the ORBITA-app\n* Life expectancy of less than 12 months.",{"count":119,"type":22},450,[25],"The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is:\n\nDoes performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life?\n\nResearchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention and coronary function testing in the intervention arm\n* Undergo percutaneous coronary intervention in the control arm",[123,124,125,126,28],"Coronary Artery Disease (CAD)","Obstructive Coronary Artery Disease","Coronary Microvascular Dysfunction (CMD)","Vasospasm, Coronary",[128,129,130],"Coronary Function Testing","Percutaneous Coronary Intervention","Stable Angina","2026-04-30",{"date":106,"type":40},{"date":106,"type":22},{"date":135,"type":22},"2029-03-01",{"name":137,"class":47},"UMC Utrecht",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":89,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100597796","tte-improves-clinical-management-of-stable-chest-pain-100597796","NCT07063147","TTE Improves Clinical Management of Stable Chest Pain","Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography","TICM-SCP","Inclusion Criteria:\n\n* symptomatic patients with SCP suspected of obstructive CAD.\n* referred for TTE for the assessment of SCP.\n* ≥18 years of age.\n* signed informed consent.\n\nExclusion Criteria:\n\n* acute coronary syndromes\n* previous CAD or coronary revascularization\n* nonsinus rhythm\n* cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons",{"count":147,"type":22},50000,"10 Years","The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.",[151,28,64,152,153],"Transthorcic Echocardiography","Major Adverse Cardiac Events","Invasive Coronary Angiography","RECRUITING","2025-07-15",{"date":157,"type":40},"2025-07-18",{"date":159,"type":40},"2025-01-01",{"date":161,"type":22},"2040-12-31",{"name":163,"class":47},"Tianjin Chest Hospital",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100562719","phase-4-the-effects-of-tirzepatide-in-people-with-overweightobesity-and-coronary-artery-disease-100562719","NCT06606821","The Effects of Tirzepatide in People With Overweight\u002FObesity and Coronary Artery Disease","The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study","IDEAL-COR","Inclusion Criteria:\n\n* Informed written consent\n* BMI equal to or above 27 kg\u002Fm2\n* Age 18 years or older\n* Referred to coronary angiogram (CAG) due to stable angina\n* Coronary atheromatosis by angiography (obstructive or non-obstructive)\n* LCBI4mm \\>200 by NIRS in a vessel not subjected to coronary intervention\n\nExclusion Criteria:\n\n* History of diabetes or HbA1c ≥48 mmol\u002Fmol (6.5%) at baseline\n* Treatment with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)\n* History of coronary artery bypass surgery (CABG)\n* Planned CV intervention (including percutaneous coronary intervention, cardiac surgery or transcatheter valve intervention) at time of randomisation\n* History of heart failure New York Heart Association (NYHA) class III or IV\n* Left ventricular ejection fraction (LVEF) ≤35%\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.53 m2\n* History of pancreatitis or plasma amylase \\>2 times upper normal limit\n* Impaired hepatic function at baseline (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 times the upper limit of normal)\n* Pregnancy, planned pregnancy or breastfeeding\n* Family or history of multiple endocrine neoplasia (MEN) type 2 or familial medullary thyroid carcinoma (FMTC)\n* Hypersensitivity to the active substance (Tirzepatide) or to any of the excipients\n* Left main stenosis (≥50% diameter or haemodynamically significant)\n* Chronic total occlusion of any major coronary vessel\n* Multi-vessel disease or complex anatomy potentially requiring coronary bypass surgery\n* Coronary anatomy or pathology precluding the safe performance of intravascular imaging in all major coronary arteries not subjected to intervention",{"count":173,"type":22},124,[61],"The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.",[64,177,178,28,179,180],"Coronary Microvascular Dysfunction","Overweight or Obesity","Chronic Coronary Artery Disease","Atherosclerosis Cardiovascular Disease",[182,183,184,185,186,28],"NIRS","IVUS","GLP-1","Tirzepatide","Intravascular imagining","2025-05-19",{"date":189,"type":40},"2025-05-22",{"date":191,"type":40},"2024-10-01",{"date":193,"type":22},"2028-08-01",{"name":195,"class":47},"Tina Vilsbøll",3,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100588722","a-multi-center-real-world-clinical-trial-of-caimr-on-two-specific-kinds-of-patients-100588722","NCT06945094","A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients.","A Multi-center, Real-World Clinical Trial on Assessment of Microcirculatory Status Using Online Coronary Angiography-Derived Index of Microcirculatory Resistance (caIMR) (Flash V)","FlashV","Inclusion Criteria:\n\n1. Age between 18 and 80 years, regardless of gender;\n2. Diagnosed with stable angina, unstable angina, or suspected myocardial ischemia;\n3. targeted vessel stenosis \\\u003C 50% and caIMR values between 20 and 30; or\n\n(3) Targeted vessel stenosis \\\u003C 50%, but with lesion length \\> 20 mm and caFFR \\> 0.8, representing diffuse disease.\n\nExclusion Criteria:\n\n1. Previously undergone percutaneous coronary intervention (PCI);\n2. History of heart failure or myocardial infarction;\n3. Acute myocardial infarction;\n4. Primary or secondary cardiomyopathy;\n5. Primary or secondary severe valvular heart disease;\n6. Severe systemic infections;\n7. Malignant cachectic diseases and an estimated survival of less than one year;\n8. Patients who are currently participating in other clinical trials involving drugs or devices and have not yet reached the primary endpoint of those trials;\n9. Patients whom the investigator deems to have other conditions that make them unsuitable for participation in the clinical trial.","80 Years",{"count":207,"type":22},508,"The coronary angiography-derived index of microcirculatory resistance (caIMR) can be used to provide a binary assessment whether patients（with stable angina, unstable angina, suspected myocardial ischemia, or coronary artery stenosis of less than 50%, and without cardiomyopathy or obstructive epicardial coronary artery disease） have microcirculatory dysfunction, using a cutoff value of 25.\n\nThis study aims to evaluate the binary classification performance of caIMR in two specific groups of patients: (1) those with caIMR values between 20 and 30, and (2) those with diffuse disease. We will do this by looking at differences in their Seattle Angina Questionnaire (SAQ) scores and their health outcomes over a three-year period.",[125,28,210,211],"Unstable Angina Pectoris","Myocardial Ischemia, Angina Pectoris",[213,214,215,216,217],"Hemodynamics","Computational fluid dynamics","Angiography-derived IMR","coronary microvascular dysfunction","stable and unstable angina","2025-04-24",{"date":220,"type":40},"2025-04-27",{"date":222,"type":22},"2025-07-01",{"date":224,"type":22},"2029-12-30",{"name":226,"class":47},"Ge Junbo",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":48},"100465926","phase-4-efficacy-and-safety-of-aspirin-in-patients-with-chronic-coronary-syndromes-without-revascularization-100465926","NCT05347069","Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization","ASA-IN","Inclusion Criteria:\n\n* Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels\u002Fmajor branches on coronary CT or coronary angiography but not eligible for coronary revascularization\n* Patients for whom consent can be obtained\n\nExclusion Criteria:\n\n* Patients with history of acute coronary syndromes (ACS)\n* Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\n* Patients with left main trunk stenosis (≥50%)\n* Patients for whom aspirin administration is mandatory\n* Patients undergoing antithrombotic therapy other than aspirin\n* Patients with atrial fibrillation\n* Patients with history of stroke within six months\n* Patients scheduled for major surgical procedures that will require aspirin discontinuation\n* Patients with contraindication of aspirin\n* Patients expected to have a prognosis of 1 year or less due to comorbidities\n* Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization\n* Patients who are judged by attending physicians to be inappropriate to participate in this study","20 Years",{"count":236,"type":22},2890,[61],"The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.",[28,64,92],[241,242],"Chronic Coronary Syndrome","Aspirin","2025-03-08",{"date":245,"type":40},"2025-03-11",{"date":247,"type":40},"2022-06-14",{"date":249,"type":22},"2030-12",{"name":251,"class":47},"Takeshi Morimoto"]